1466 INCIDENCE OF HEMATURIA FOLLOWING TUR-BT AMONG 1315 PATIENTS RECEIVING ANTI-PLATELET THERAPY
Notice bibliographique
Résumé
You have accessJournal of UrologyBladder Cancer: Superficial II1 Apr 20101466 INCIDENCE OF HEMATURIA FOLLOWING TUR-BT AMONG 1315 PATIENTS RECEIVING ANTI-PLATELET THERAPY Blair Egerdie, Shanta Chawla, Chris Nardo, and Bela Denes Blair EgerdieBlair Egerdie Kitchener, Canada More articles by this author , Shanta ChawlaShanta Chawla Irvine, CA More articles by this author , Chris NardoChris Nardo Irvine, CA More articles by this author , and Bela DenesBela Denes Irvine, CA More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1181AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Currently, there are no clear compelling data that describe the risk of post TUR-BT hematuria for patients on anti-platelet therapy (APT). The present analysis examines the impact of APT on hematuria reported in 1315 patients randomized to either apaziquone or placebo, across 2 ongoing Phase 3 studies. METHODS We surveyed the databases from two ongoing studies (SPI 611/612) of low risk NMIBC patients receiving an immediate post TURBT instillation of apaziquone or placebo followed for 2 years. Use of anti-platelet medication was collected and categorized as taking Aspirin (ASA), clopidogrel, or both at study entry. Incidence and severity of physician reported post randomization hematuria was compared between patients who were and who were not taking APT using Pearson¡¦s Chi-Square statistic. A 2-tailed Fisher¡¦s Exact test was used to confirm the results when the sample size was small (<20) for any of the categories. The relative risk (RR), and corresponding 95% confidence interval (CI), of hematuria for patients on APT is reported. RESULTS The median patient age was 68 years (range 22-94). 414 patients (31%) reported ASA and/or clopidogrel use at the time of randomization. 347 of these patients (84%) were on ASA alone, while 67 (16%) were on clopidogrel +/- ASA. 134 incident cases of hematuria were reported after randomization. 57 were among patients on ASA+/-clopidogrel (13.8%) compared to 77 (8.5%) for patients not on either drug (fÓ2 = 8.45, p=0.004). The RR of hematuria for patients on APT was 1.61 (1.17-2.22)., The incidence of hematuria for 43 patients on ASA therapy alone was 12.4% (fÓ2 = 1.93, p=0.165) with a RR of 1.27 (0.91-1.79) compared to patients not on APT. For patients on clopidogrel or clopidogrel containing regimens the incidence was 20.9% (14/67; fÓ2 = 8.84, p=0.003) with a RR of 2.17 (1.32-3.57). Hematuria was reported as a serious adverse event (SAE) in 13 of 901 (1.4%) patients not on anti-platelet therapy, 4 of 347 (1%) patients on ASA alone and 5 of 67 (7%) on Plavix or combination therapy. CONCLUSIONS Anti-platelet therapy, specifically regimens with clopidogrel, may more than double the risk of hematuria in patients with NMIBC post TUR-BT however the overall risk of hematuria related SAEs remains low (9/414; 2.1%). For patients on ASA alone it is similar to those not on APT (1.4%vs. 1%; p =0.82) but is higher with the addition of clopidogrel alone or in combination. With the increasing use of APT in aging populations, Urologists should be aware of these additional risks. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e564-e565 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Blair Egerdie Kitchener, Canada More articles by this author Shanta Chawla Irvine, CA More articles by this author Chris Nardo Irvine, CA More articles by this author Bela Denes Irvine, CA More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction machine sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Le volet Gemma est une étiquette directe du modèle pour chaque travail de la base, lue sur la notice réduite au titre. Le volet Codex est un classifieur appris des 10 348 étiquettes directes de Codex et calibré sur les taux pondérés de l'échantillon; les champs sans appui suffisant ne portent aucun appel Codex. Le mode candidate est l'union des deux volets; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont pas des étiquettes humaines.
Scores du classifieur distillé par catégorie (deux têtes)
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,001 | 0,003 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,001 |
| Bibliométrie | 0,002 | 0,002 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,001 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,004 | 0,001 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule source (Gemma direct ou Codex distillé), pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».